# Immunetrics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunetrics

- Industry: Software
- Headquarters: Pittsburgh, US
- Website: www.immunetrics.com
- Total disclosed funding: $0.1M
- Latest round: Seed (Oct 19, 2005)
- Investors on record: 1

## About

Immunetrics, Inc., located in Pittsburgh, US, specializes in providing advanced biopharmaceutical modeling and simulation solutions, supporting the pharmaceutical and biotechnology industries with innovative approaches to drug discovery and development.Founded in 2001 in Pittsburgh, US, Immunetrics, Inc. focuses on biopharmaceutical modeling solutions. The company has undergone strategic changes, including its recent acquisition by Simulations Plus, Inc. on June 20, 2023, for USD 15.5 mn, marking a significant shift in its operational strategy. The firm has been involved in a total of 3 deals, with its latest funding coming from a Trade Sale. The CEO of Immunetrics is Steve Chang, with the founder being Mitchell Fink.Immunetrics offers a comprehensive suite of innovative software solutions and consulting services tailored for the pharmaceutical and biotechnology sectors. Core products include modeling and simulation software, which are essential tools in drug discovery and development processes. These solutions enable clients to simulate pharmacokinetics, predict drug absorption and metabolism, and assess potential toxicity. With over 25 years of industry experience, Immunetrics serves a diverse client base, including major pharmaceutical companies and biotech firms across North America, Europe, and Asia.Immunetrics generates revenue primarily through the sale of software licenses and consulting services. The company employs a subscription-based model, allowing clients access to tailored software tools for drug development. Revenue is complemented by consulting services that offer expert support in quantitative systems pharmacology and pharmacokinetics/pharmacodynamics. Key products contributing to revenue include flagship software tools, fostering long-term relationships with clients through annual subscriptions and consulting fees.Following its acquisition in June 2023, Immunetrics plans to enhance its research and development infrastructure, leveraging the resources provided by Simulations Plus, Inc. The company aims to introduce new software solutions aimed at improving drug development efficiencies, with timelines for product releases to be announced. Immunetrics is also targeting expansion into new geographic markets, specifically focusing on Europe and Asia, in the coming years. The recent funding from the acquisition will be utilized to support these growth initiatives and strengthen operational capabilities.

## Funding rounds

- Seed, Oct 19, 2005, $0.1M — Pittsburgh Life Sciences Greenhouse

## Investors

- Pittsburgh Life Sciences Greenhouse (https://capitalatlas.ai/funds/pittsburgh-life-sciences-greenhouse) — Seed